Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: Results of the VOSIFI study

Haematologica

Volumn 95, Issue 10, 2010, Pages 1762-1768

  Cordonnier, Catherine ^a   Rovira, Montserrat ^b   Maertens, Johan ^c   Olavarria, Eduardo ^d   Faucher, Catherine ^e   Bilger, Karin ^f   Pigneux, Arnaud ^g   Cornely, Oliver A ^h   Ullmann, Andrew J ⁱ   Bofarull, Rodrigo Martino ^j   de la Cämara, Rafael ^k   Weisser, Maja ^l   Liakopoulou, Effie ^m   Abecasis, Manuel ⁿ   Heussel, Claus Peter ^o   Pineau, Marc ^p   Ljungman, Per ^q   Einsele, Hermann ^r  

^a HENRI MONDOR HOSPITAL   (France)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e INSTITUT PAOLI CALMETTES   (France)

^f HÔPITAL DE HAUTEPIERRE   (France)

^g HAUT LÉVÊQUE HOSPITAL   (France)

^h UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

ⁱ UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^j HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^k HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^l UNIVERSITY HOSPITAL BASEL   (Switzerland)

^m CHRISTIE HOSPITAL   (United Kingdom)

ⁿ INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^o UNIVERSITY OF HEIDELBERG   (Germany)

^p Pfizer Global Pharmaceuticals   (France)

^q KAROLINSKA INSTITUTE   (Sweden)

^r UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

more..

Author keywords

Allogeneic; Fungal; Prophylaxis; Transplant; Voriconazole

Indexed keywords

VORICONAZOLE;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; ASPERGILLOSIS; CANDIDEMIA; CANDIDIASIS; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; HYPERTENSION; INSOMNIA; LIVER TOXICITY; LOADING DRUG DOSE; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; PSEUDALLESCHERIASIS; RECIPIENT; RELAPSE; SECONDARY PREVENTION; SYSTEMIC MYCOSIS; THROMBOCYTOPENIA; TREATMENT DURATION; VISUAL HALLUCINATION; VOMITING; ZYGOMYCOSIS;

EID: 77956489402     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.020073     Document Type: Article

References (33)

1. Thursky K, Byrnes G, Grigg A, Szer J, Slavin M. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant. 2004;34(2):115-121.
2. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002; 100(13):4358-4366.
3. Guiot HF, Fibbe WE, van't Wout JW. Risk factors for fungal infections in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis. 1994;18(4):525-532.
4. Cordonnier C, Pautas C, Maury S, Bastié JN, Chehata S, Castaigne S, et al. Secondary prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant. 2004;33(9):943-948.
5. Offner F, Cordonnier C, Ljungman P, Prentice HG, Engelhard D, De Bacquer D, et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis. 1998;26(5):1098-1103.
6. Fukuda T, Boeckh M, Guthrie K, Mattson DK, Owens S, Wald A, et al. Invasive aspergillosis before allogeneic hematopoetic stem cell transplantation: 10 year experience at a single transplant center. Biol Blood Marrow Transplant. 2004;10(7):494-503.
7. Martino R, Parody R, Fukuda T, Maertens J, Theunissen K, Ho A, et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2006;108(9):2928-2936.
8. Sipsas NV, Kontoyiannis DP. Clinical issues regarding relapsing as pergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies. Clin Infect Dis. 2006;42(11):1584-1591.
9. Cornely OA. Aspergillus to zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections. Infection. 2008;36(4):296-313.
10. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335-347.
11. Johnson E, Espinel-Ingroff A, Szekely A, Hockey H, Troke P. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies. Int J Antimicrob Agents. 2008;32(6):511-514.
12. Espinel-Ingroff A, Johnson E, Hockey H, Troke P. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole phase III clinical studies. J Antimicrob Chemother. 2008;61(3):616-620.
13. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002; 347(6):408-415.
14. Dignan F, Grigoriadou V, Maxwell F, Evans S, Riddell A, Shaw B, et al. Effective secondary antifungal prophylaxis with voriconazole. Presented at the 13th Congress of the EHA - European Hematology Association; Copenhagen, Denmark; June 12-15, 2008. [Abstract 0183].
15. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34(1):7-14.
16. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44(10):1289-1297.
17. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999; 18(6):695-706.
18. Cordonnier C, Beaune J, Offner F, Marinus A, Ljungman P, Meunier F. Aspergillosis prior to bone marrow transplantation. Infectious diseases working party of the EBMT and the EORTC invasive fungal infectious cooperative group. Bone Marrow Transplant. 1995;16(2):323-324.
19. Martino R, Lopez R, Sureda A, Brunet S, Domingo-Albós A. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemotherapy: a single center experience and review of the literature. Haematologica. 1997;82(3):297-304.
20. Kruger WH, Russmann B, de Wit M, Kröger N, Renges H, Sobottka I, et al. Haema -topoetic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B. Acta Haematol. 2005;113(2):104-108.
21. Bjerke JW, Meyers JD, Bowden RA. Hepatosplenic candidiasis- a contraindication to marrow transplantation? Blood. 1994;84(8):2811-2814.
22. Allinson K, Kolve H, Gumbinger HG, Vormoor HJ, Ehlert K, Groll AH. Secondary antifungal prophylaxis in paediatric allogeneic haematopoeitic stem cell recipients. J Antimicrob Chemother. 2008;61(3):734-742.
23. Hill BT, Kondapalli L, Artz A, Smith S, Rich E, Godley L, et al. Successful allogeneic transplantation of patients with suspected prior invasive mold infection. Leuk Lymphoma. 2007;48(9):1799-1805.
24. De Fabritiis P, Spagnoli A, Di Bartolomeo P, Locasciulli A, Cudillo L, Milone G, et al. Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with pulmonary and/or systemic fungal infection. Bone Marrow Transplant. 2007;40(3):245-249.
25. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348-359.
26. Richardson M, Lass-Flörl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect 2008;14(suppl 4):5-24.
27. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomized non-inferiority trial. Lancet. 2005; 28;366 (9495):1435-1442.
28. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008; 46(3):327-360.
29. Thursky KA, Playford EG, Seymour JF, Sorrell TC, Ellis DH, Guy SD, et al. Recommendations for the treatment of established fungal infections. Intern Med J. 2008;38(6b):496-520.
30. Prentice AG, Glasmacher A, Hobson RP, et al. Guidelines on the management of invasive fungal infection during therapy for haematological malignancy. BCSH Guidelines Home Page. Available at URL: www.bcshguidelines.com/pdf/IFI_therapy.pdf. Accessed Sep 14, 2009.
31. Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Böhme A, Ruhnke M, Buchheidt D, Cornely OA, Einsele H, et al. Treatment of invasive fungal infections in cancer patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2009;88(2):97-110.
32. Troke P, Aguirrebengoa K, Arteaga C, Ellis D, Heath CH, Lutsar I, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother. 2008;52(5):1743-1750.
33. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36(9):1122-1131.